A carregar...
Incidence and Risk of QTc Interval Prolongation among Cancer Patients Treated with Vandetanib: A Systematic Review and Meta-analysis
BACKGROUND: Vandetanib is a multikinase inhibitor that is under assessment for the treatment of various cancers. QTc interval prolongation is one of the major adverse effects of this drug, but the reported incidence varies substantially among clinical trials. We performed a systematic review and met...
Na minha lista:
| Main Authors: | , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Public Library of Science
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3281826/ https://ncbi.nlm.nih.gov/pubmed/22363427 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0030353 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|